Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Polaryx Therapeutics Inc's Competitiveness

Name: Polaryx Therapeutics Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Polaryx Therapeutics Inc (PLYX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q1 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/PLYX/competitors                    

                        https://api.csimarket.com/api/v1/companies/PLYX/relationships                    

                        https://api.csimarket.com/api/v1/companies/PLYX/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Polaryx Therapeutics Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Polaryx Therapeutics Inc	-	-	-	Yes
Similar-Size Competitors (9)	-

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

PLYX Stock Performance relative to its Competitors

PLYX Competitors (weighted) Percent change over the selected range

Polaryx Therapeutics Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(1 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Polaryx Therapeutics Inc	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Polaryx Therapeutics Inc's competitor groups requires a Commercial License.

Unlock Full Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

PLYX Stock Performance relative to High-Confidence Competitors

PLYX High-Confidence Competitors (equal-weighted, 1) Percent change over the selected range

PLYX Stock Performance relative to Similar-Size Competitors

PLYX Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Polaryx Therapeutics Inc's Comment on Competition and Industry Peers

The company operates in a competitive environment that includes major pharmaceutical companies, specialty pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and public and private research organizations worldwide. For the treatment of the 13 sub-types of neuronal ceroid lipofuscinoses (NCLs), cerliponase alfa is the established standard of care for CLN2 disease. The company is aware of other entities, including Forge Biologics (Ajinomoto), developing competitive product candidates in this area. For Niemann-Pick disease (NPD) types A and B, olipudase alfa is the established standard of care, and the company is not aware of other competitive treatments currently in development. Additional potential competitors include academic institutions, government agencies, and other public and private research organizations engaged in research, patent protection, and collaborative efforts related to research, development, manufacturing, and commercialization.

Competitor data is not yet available for Polaryx Therapeutics Inc.

Polaryx Therapeutics Inc's Competitors Named by the Company

Competitive relationships identified from Polaryx Therapeutics Inc reports and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Forge Biologics (Ajinomoto)	Company report	85%	2022 to 2026	3

Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Polaryx Therapeutics Inc's named competitors require a Commercial License.

Unlock Full Access

Methodology: relationships are extracted from Polaryx Therapeutics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.